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"Here in Singapore the abuse of heroin has 
increased alarmingly - a small epidemic to 
quote the Govt. Schoolchildren in their early 
teens are now involved. The govt. has brought 
in very tough legislation, A person found in 
possession of more than 3 g (Gm) morphine or 
2 g heroin is presumed, until contrary is 
proved, to be a drug trafficker. Maximum 
sentence is 20 years and 20 strokes of the 
cane. For trafficking in more than 15 g of 
heroin (or 30 g morphine) the penalty is 
death, One such case will be coming up to the 
courts soon. Suspected abusers must supply 
urine samples for tests and if any controlled 
drug is found in the urine, the person is pre-
sumed to have consumed the drug and thus 
committed an offence. Thus it will not be a 
defence, as before, that the person may have 
been administered the drug without his know-
ledge in a drink, cigarette etc. He is guilty 
unless he can prove his innocence." 
Personal Communication ( A1:1 to JKB) April 197 6. 
THE USE OF NARCOTIC ANTAGONISTS IN RELATION TO OPIATE-TYPE DRUG DEPENDENCE 
Fries, PhD and William G. Reifenrath, PhD; Section of Medicinal Chemistry, School of 
, University of the Pacific, Stockton, California 95211 · 
INTRODUCTION 
Narcotic antagonists are drugs which reverse the pharmacological effects of morphine, 
other narcotic analgetics. The first narcotic antagonist was reported by Pohl(l). 
to improve the analgetic (pain-killing) properties of codeine, he synthesized 
noJrccJaE•~n.e and found that it unexpectedly antagonized the respiratory depression and 
3. 
by morphine. This finding lay dormant until the synthesis of N-allylnormorphine 
~Jor]pn:cn,,,(2,3) which was found to antagonize most of the actions of morphine(4). The initial 
of nalorphine lYas to test for physical dependence in individuals suspected to be 
to heroin-like agents. Later nalorphine was realized to be life saving in cases of 
overdose. Continued studies also revealed nalorphine to have strong analgetic prop-
man. These -interesting properties of nalorphine provided the impetus for development 
narcotic antagonists and also of other compounds possessing a mixture of analgetic and 
properties. 
Recently narcotic antagonists have been studied for use in postdetoxification treatment of 
, with the aim that pretreatment of individuals with an antagonist will provide protec-
t the pharmacological actions of those narcotics responsible for heroin-like drug 
(5). 
review is an attempt to explain the current status of narcotic antagonists as they 
drug therapy (treatment of opiate overdosage) and drug abuse (management of the post 
opiate addict). All individuals using these agents should have a thorough under-
of their pharmacological actions. These narcotic antagonists are currently the most 
antidote available for heroin overdosage and act within seconds o f injection. They are 
saving compounds and are stocked in the emergency rooms of practically all hospitals today. 
CHEMISTRY 
Narcotic antagonists are structurally very similar to parent narcotic agents. At this time 
clinically useful antagonists have resulted from the replacement of the N-methyl group on 
parent narcotic with an N-allyl or N-methylcyclopropyl group. The structures and names of 
narcotic antagonists that are curre;tly available are given in Table I. 
general, antagonists with an N-methylcyclopropyl (as in cyclazocine) group have a longer 
of action than those with an-N-allyl moiety (nalorphine, naloxone, and levallorphan). 
~·'"''u'·"un of hydroxyl at the 14-position of the morphine nucleus (as in naloxone) imparts 
and purer antagonistic activity. The 4-5 ether bridge in nalorphine or naloxone does 
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Table I. Currently Marketed Narcotic Antagonists 
STRUCTURE PARENT NARCOTIC 
NARCOTIC ANTAGONIST 
~ 
R Name R Name 
-) 
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for antagonist activity and may promote fast er metabolism a t the C-3 posi-
a desirable feature in the design of longer acting antagonists(6). 
PHARMACOLOGY 
Narcotic antagonists are capable of reversing effects such as analgesia, sedation, eupho-
gastrointestinal effects, and the frequently lethal respiratory depression caused by mor-
and its surrogates. These antagonists are specific in that they will not reverse depres -
ting from other classes of drugs such as barbiturates. They are also worthless in 
overdosage with stimulants (such as cocaine and the amphetamines). However naloxone 
recently been reported to reverse the effects of large doses of diazepam (Va liumR)(7). 
Nalorphine and levallorphan are termed partial-antagonis ts or mixed agonist- antagonists for 
following reasons. lfhen these agents are administered to normal persons, they mimic to 
degrees the effects seen with morphine administration (agonist effects). However, when 
a re given to persons dependent on opiates or who have opiates present in their 
, these partial antagonists 11 reverse 11 the effect s of the opiate. Naloxone displays very 
if any agonist effects when given to normals and is therefore termed a pure antagonist. 
pentazocine is a mixed agonist-antagonist, its antagonist component is weak and it is 
useful in cases of narcotic overdose. It is used primarily as an analgetic . 
general the agonist- antagonists have a low potential for drug dependence. In studies 
chronic administration of nalorphine, cyclazocine and pentazocine, abrupt withdrawal 
an abstinence syndrome which was relatively mild compared to morphine (8,9,10). Asso-
with their agonist component, these agents can produce significant respiratory depres-
Agents of this class can also produce psychotomimetic effects (disorientation, halluci-
' etc.), particularly when both agonist and antagonist properties are strong(ll) . 
pure antagonists (naloxone) by definition have no agonist properties . They will not 
analgesia, respiratory depression, pupillary constriction, or psychotomimetic effects 
ical dependence is not possible. Tolerance to the antagonist properties is also not 
on chronic administration(ll,l2). 
be emphasized again that these antagonists will not reverse respiratory depres-
the barbiturates. In fact, nalorphine and levallorphan may even worsen barbi-
~r•a tE•-induced or al cohol-induced respiratory depression because of their agonist activity. In 
the cause of respiratory depression is not clear, or if drugs in addition to 
suspected in the depression, naloxone is indicated since it produces no respiratory 
its own. It should also be cautioned that administration of any antagonist to 
precipitate a severe withdrawal syndrome which can be more dangerous than the res -
depression; however, administration of the antagonists in small doses over a period of 
minutes will reduce the chance of this happening. Further, narcotic overdose cases 
1,,~•c c.La''~Y methadone) treated with antagonists should be observed periodical ly , since the dura-
the antagonist may be shorter than the narcotic causing the respiratory depression. The 
of the antagonist may wear off before those of the narcotic, and life-threatening res-
depression may again result, requiring the administration of more antagonist. Over-
patients should always be under qualified medical supervision. 
Nalorphine (Nalline HClR, Merck, Sharp and Dohme) . Nalorphine shows little evidence of 
activity in most animal studies except in the rat. However, in man it is as potent 
as morphine(l3). As is typical of partial antagonists, "addiction" liability is 
to morphine or heroin. Unfortunately, the compound produces psychotomimetic 
analgetic doses . 
absorbed after subcutaneous administration and quickly crosses the 
site of action. It is excreted rapidly via the urine. Its duration 
shorter than its parent compound, morphine . 
is useful in the treatment of narcotic overdosage to combat the severe respira-
caused by morphine, codeine, heroin, and similar agents . Nalorphine has also 
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been used as a diagnostic agent for opiate abuse (Nalline test)--a positive response being 
cated by a prompt increase in pupil size(l4). Tests of this kind should only be done by 
cians well acquainted with the procedure. The reliability of the test has been questioned 
the use of sensitive chemical tests for the presence of opiates in the urine are preferable 
medically and in courts of law(l5). 
Levallorphan (Lorphan TartrateR, Roche). Levallorphan has twice the potency of 
as an antagonist and has comparable analgetic potency(l6,17). As with nalorphine, its 
of action is significantly shorter than its parent, levorphanol. Its overall actions and 
are similar to those of nalorphine, and similar precautions should be taken in its 
Naloxone (NarcanR, Endo). Naloxone is approximately 7 times more potent than nalorphine 
an antagonist. It produces negligible side effects in normal subjects at therapeutic 
Naloxone will inhibit or reverse the effects of all opiate agonists such as morphine, 
methadone, propoxyphene (DarvonR) and meperidine (DemerolR) , Unlike nalorphine and 
naloxone is an effective antagonist of the respiratory depression caused by 
other antagonists(ll). Because naloxone is a potent, fast-acting (effects noticed 
2 minutes following intravenous administration and slightly longer intramuscularly), pure nar-
cotic antagonist that produces no respiratory depression, it is the drug of choice to combat 
respiratory depression resulting from opiate overdose. Since naloxone does not alter respira-
tory depression caused by barbiturates or other sedative-hypnotics, failure to get a response 
from naloxone is a good indication that the depression is not caused by an opiate. 
Naloxone treatment has been proposed as a means to prevent addicts from returning to drug 
use, but its short duration of action (effective levels of naloxone can be maintained in man 
for only 4 hours) (17) and poor oral activity (1-3 grams/day are required to protect against the 
effects of heroin for 24 hours)(l9) limit its use for this purpose. 
The low oral activity of naloxone (50 times less potent orally than parenterally) is uti-
lized in a preparation called MethenexR (Bristol) . This product is formulated to provide a 
ratio of 40 mg methadone HCl to 2 mg naloxone HCl. When given orally at the usual doses, the 
naloxone present does not interfere with the effects of methadone . However, administration of 
this mixture by injection results in significant reduction of the pleasing effects caused by 
methadone, thereby reducing the attractiveness of the mixture for abuse by injection(20) . 
7. 
of physical dependence is not possible in these circumstances. 
opiate use is a result of reinforcement of drug seeking behavior due 
drugs, the use of antagonists should extinguish this behavior(22,23). 
Further, if compul-







compounds presently being investiga ted as agents for treatment 
These include cyclazocine, oxilorphan and naltrexone (see struc-
@f6 NJ> ~ . HO 
Oxilorphan Naltrexone 
Cyclazocine. Cyclazocine has both potent agonist and antagonist activities . Cyclazocine 
ection is approximately 40 times more potent than morphine as an analgetic(24). Its 
t potency is slightly less than naloxone(l6) . Like nalorphine and levallorphan, cycla-
capable of producing marked respiratory depression. Although chronic administration 
to human subjects produces an abstinence syndrome on abrupt withdrawal, the 
is mild compared to morphine. 
Pentazocine (TalwinR, Winthrop) . The only antagonist currently marketed as an analgetic In doses of approximately 4 mg/day orally, cyclazocine has been found to antagonize the 
pentazocine . The presence of both agonist and antagonist activity in pentazocine has been of morphine administration for 24 hours--a mode of administration and duration of action 
demonstrated. As an analgetic it is 1/3 as potent as morphine on injection and roughly equi- for use in post-withdrawal treatment programs(5,9,18). However, the compound produces 
potent to codeine orally(21). Pentazocine has relatively weak antagonist activity, being 1/50 • hallucinations, irritability and sedation. Although thes e side effects increase in 
as potent as nalorphine in precipitating abstinence in subjects dependent on 240 mg/day of mar- the dose increases(25,26), they usually, but not always, disa ppear on continued 
phine(8). It is not used for treatment of narcotic overdoses . In general, pentazocine at the otntot·r•''On. Tolerance does not develop to the antagonist activity(25). Cyclazocine's un-
usual doses produces typical opiate CNS effects including analgesia, sedation and respiratory side effects, particularly during induction, would appear to pr event its widespread 
depression, but at higher doses produces nalorphine-like dysphoria (restlessness and anxi~ty) use(l9,27). 
It is ~ell absorbed from the gastrointestinal tract and from subcutaneous and intramuscular 
sites . As is typical of mixed agonist-antagonists, pentazocine's dependence liability is low 
and withdrawal from chronically administered pentazocine has been judged 1/3 as severe as mor-
phine . If pentazocine is administered to subjects dependent on opiates, the possibility of 
cipitating a withdrawal syndrome is present--the intensity of which is related to the level 
dependence and the dose of pentazocine given . In patients receiving opiates on a regular 
Oxilorphan has weak agonist and predominant antagonist pr operties. It has an 
potency similar to cyclazoc ine and it appears to have a long dura tion of action(28). 
been proposed for use in narcotic post-withdrawal treatment programs and studies are cur-
underway to determine the efficacy of oral administration, duration of antagonist activ-
and the level of side effects. 
an opiate-free period of 1-2 days before pentazocine administration will usually suffice 
vent withdrawal effects . Pentazocine has the ability to depress respiration, and in cases Naltrexone. Naltrexone is a pure antagonist wi th greater potency than naloxone . Having 
overdose the respiratory depression cannot be countered by nalorphine or levallorphan. ~. l nw>nel~t>nl. st properties, euphoria or physical dependence is not possible. In doses of 50-200 mg 
has been reported effective in this. regard. in clinical studies, negligible effects were observed(l2,29). It is orally active and 
te doses gives a duration of protection against opiate effects comparable to that 
with cyclazocine(30). Little toxicity data is available for naltrexone, and studies 
underway to determine its safety and utility for post-withdraw! treatment . ANTAGONISTS IN NARCOTIC ADDICTION TREATMENT 
Narcotic antagonists were proposed some time ago for use by post-withdrawal addicts. 
Ideally, if these individuals are continuously taking sufficient amounts of a narcotic antago-
nist, the effects of ordinary doses of opiates are significantly reduced or blocked entirely. 
Pacific Information Service on Street-Drugs Volume 5 No. 1 
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rehabilitation of addicts have not been impressive when compared to the methadone-main-
approach--particularly with regard to the percentage of patients becoming socially 
and the attractiveness of the method to the addict population(l8,27,31,38). Treat-
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ment with antagonists appears to require a well motivated subject with a relatively moderat 
habit(27). The dysphoric effects of cyclazocine and oxilorphan probably will prevent thesee 
from ever attaining widespread clinical use. Agents such ·as naloxone or naltrexone provide 
euphoria or reinforcing properties for the former addict and, since this individual 
get relief from heroin when life seems intolerable, he may turn to other depressant 
alcohol or barbiturates. 
The authors can see two possible modes by which narcotic antagonists may someday become 
ful in drug rehabilitation therapy. The first of these would require that courts of law 
participation in the programs mandatory for parolees whose criminal records are directly 
to use of the opiate drugs. The second would require the development of a new antagoni 
would both block the action of heroin, and induce pharmacological effects which are 
enough to substitute for the drug response which the individual is seeking. Whether such a 
can be found remains to be seen. 
CURRENT RESEARCH 
All of the compounds discussed above have chemical structures closely related to morphine. 
In the continuing search for analgetics superior to morphine, simpler compounds with mixed 
agonist-antagonist properties are being investigated. The bridged aminotetralins(33), the 
levo-isomer of 5-~-hydroxyphenyl-2-methylmorphan(34), profedol(35), prodilidine(35), and vimi-
nol(36) are among these interesting compounds. However, none of these compounds have yet 
clinical usefulness. 
OH c.? 0 -Me 
~~,~~'"'"'' .~ ,,,, 








Compounds of even·more complex structure than morphine have been synthesized. 
a bridged derivative of thebaine, has been proposed for clinical trials because of 
pharmacological results in animals(37). The compound has shown potent agonist and antagonis t 
activity in rodents. It does not produce physical dependence on chronic administration to mice 
or monkeys. In clinical studies at doses of 2 ~g/kg intravenously or intramuscularly and 
40 ~g/kg orally, doses which have shown significant blockade of experimentally-induced pain, no 
signs of dysphoria were observed. 
Buprenorphine 
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current research to develop antagonists of long duration through modification of the dosage 
of existing ant.agonists is in progress. Most clinicians indicate a preference for an 
of s.everal days or weeks duration, as this would require less motivation of former 
in rehabilitation programs. In one study, to determine the feasibility of slow-release 
of naltrexone, the drug was suspended in small particles of polylactide plastic. In 
dose blocked the effects of .morphine for a period of 20-30 days(38). Alza Cor-
Alto, California, is also examining the development of polymers that can.be used 
of drugs, including naloxone, to provide slow release. At the present t1me, all 
preparations require much further testing and clinical study to determine their safety 
utility· 
SUMMARY 
antagonists to counter life-threatening respiratory depression result-
is well established. The role of antagonists in post-withdrawal man-
of the addict is yet to be determined. Certainly the antagonists should not be regarded 
answer to opiate abuse, but rather as a potentially powerful tool to aid the clini:ian 
worker in the overall treatment of narcotic drug dependence. Researchers cont1nue 
investigate the antagonists not only with the hope of discovering more effective 
for the treatment of heroin-like drug dependence, but also of finding a strong analgetic, 
of side effects and without potential for dependence. 
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NEWS AND COMMENT 
A new street-drug analysis laboratory. Further information may be obtained 
writing to: 
The Branan Drug Analysis and Toxicology Laboratory, 
345 Boulevard, N. E. 
Altlanta, Georgia 30312 Telephone (404) 688-4400 
An excellent publication has just come to our attention and we are listing i 
because it does seem to fulfill a need in toxicology. 
Charles L. Winek, Editor and Sydney P. Shanor, Assistant Editor 
TOXICOLOGY ANNUAL 1974 
New York NY: Marcel Dekker, Inc., 1975 
A very interesting article related to the topic in this issue 
is ln the above publication. 
Another publication has come to our attention (1~e have not seen a copy) that 
could be very useful in street-drug analysis. 
N. H. Choulis. IDENTIFICATION PROCEDURES OF DRUGS OF ABUSE. 
Publisher etc., not avaiiable --write to: 
Professor N. H. Choulis 
School of Pharmacy 
West Virginia University 
Morgantown, West Virginia 26506 
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